dipyridamole has been researched along with Chronic Kidney Diseases in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dipyridamole treatment was associated with decreased odds for rapid eGFR decline [odds ratio, 0." | 1.40 | Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease. ( Chen, HC; Hung, CC; Hwang, SJ; Kuo, HT; Lim, LM; Lin, HY; Lin, MY; Tsai, JC; Yang, ML, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hung, CC | 1 |
| Yang, ML | 1 |
| Lin, MY | 1 |
| Lin, HY | 1 |
| Lim, LM | 1 |
| Kuo, HT | 1 |
| Hwang, SJ | 1 |
| Tsai, JC | 1 |
| Chen, HC | 1 |
1 other study available for dipyridamole and Chronic Kidney Diseases
| Article | Year |
|---|---|
Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease.
Topics: Creatinine; Demography; Dipyridamole; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Ch | 2014 |